Pueraria mirifica for Health & Longevity - Quick Reference Sheet

Pueraria mirifica for Health & Longevity

Created on 10/18/2026 – Quick Reference based on Evidence Review created using AI4L + evidence-mcp / Gemini 4 Argon – Audit

Pueraria mirifica is a Southeast Asian root plant used as an oral supplement or vaginal gel for menopausal symptoms, vaginal health, and bone maintenance. Its compounds strongly bind estrogen receptors, with medium evidence for vaginal restoration and reduced bone breakdown, and low, conflicted evidence for hot flashes, cholesterol, and wrinkles. Oral use carries inflammation, bleeding, liver, heart rhythm, and supplement-quality risks, giving vaginal gel a narrower risk profile. (Full Review)

Protocol

Low-dose oral regimen
20–50 mg/day
Standardized root capsules once daily; 25 mg/day matches 50 mg/day in postmenopausal females
Intravaginal gel protocol
0.5 g of 5%–6% gel
Once daily for 2 weeks, followed by 0.5 g three times weekly for 10 weeks
Optimal time of day
Morning (oral) / Nightly (gel)
Oral dosing with a fat-containing meal aids absorption and minimizes transient insomnia
Time to effect
Vaginal Atrophy, Microenvironment & Genitourinary Symptoms
4–12 weeks
Vaginal perfusion improves within 4 weeks and epithelial maturation by 6–12 weeks (5%–6% gel)
Suppression of Postmenopausal Bone Turnover
24 weeks
Serum bone-specific alkaline phosphatase reduction with 20–50 mg/day oral dosing
Menopausal Vasomotor & Climacteric Symptom Relief
4–24 weeks
Vasomotor scores decline within 4 weeks of oral dosing (25–100 mg/day), reaching maximal reduction by 12–24 weeks

Benefits

Contraindications
  • Pregnant or lactating individuals
  • Individuals with estrogen-dependent neoplasia or precancerous endometrial or breast conditions
  • Individuals with congenital or acquired long QT syndrome
  • Individuals with liver dysfunction, pulmonary embolism, anemia, or hypertriglyceridemia
  • Premenopausal women and young adults (<30 years) seeking cosmetic effects
Key Interactions
  • Selective estrogen receptor modulators (tissue-selective estrogen blockers) and aromatase inhibitors (estrogen-synthesis blockers; tamoxifen, letrozole) (theoretical)
  • Systemic estrogens and oral contraceptives (estradiol, ethinyl estradiol) (theoretical)
  • CYP1A2 substrates and over-the-counter stimulants (tizanidine, theophylline, caffeine) (theoretical)
  • Corticosteroids, hydantoins (anticonvulsant seizure medications), and thyroid hormones (prednisone, phenytoin, levothyroxine) (theoretical)
  • Over-the-counter QT-prolonging medications (diphenhydramine, loperamide) (theoretical)
  • Additive phytoestrogen and hepatotoxic supplements (soy isoflavones, red clover, black cohosh) (theoretical)

Risk & Side Effects

  • High:
  • Medium: Systemic inflammatory marker elevation
  • Low: Abnormal vaginal bleeding, menstrual disruption & mastodynia; hypertriglyceridemia; transient anemia, hepatic enzyme elevation & renal marker shifts; QT interval prolongation & torsades de pointes
  • Speculative: Mammary carcinogenesis & endometrial hyperplasia promotion; intrahepatic cholestasis; gonadotropin suppression, anovulation & male testicular suppression

Monitoring

Marker Target Why
Bone-Specific Alkaline Phosphatase (BAP) No established target; reduction from individual baseline Expected efficacy marker: oral dosing (20–50 mg/day) suppressed postmenopausal bone turnover over 24 weeks
LDL & HDL Cholesterol No established target; LDL decrease and HDL increase from individual baseline Expected efficacy marker: 100 mg/day oral dosing lowered LDL by 17% and raised HDL by 34% in 8 weeks, though 20–50 mg/day showed no change
Fasting Serum Triglycerides <150 mg/dL (standard reference range) Safety check: oral estrogenic stimulation can elevate hepatic triglyceride synthesis and cause progressive hypertriglyceridemia
High-Sensitivity C-Reactive Protein (hs-CRP) No established target; stability relative to individual baseline Safety check: clinical trial synthesis reported a doubling of serum C-reactive protein during oral use
ALT, AST & Complete Blood Count ALT 7–56 U/L, AST 8–33 U/L, female hemoglobin 12.0–16.0 g/dL (standard reference range) Safety check: screens for transient hepatic enzyme elevations, cholestasis, and transient anemia reported in Phase II trials
Endometrial Thickness & Vaginal Maturation Index (VMI) No established target; endometrial thickness stability and VMI increase from individual baseline Safety check and expected efficacy marker: confirms vaginal epithelial restoration while ruling out estrogen-induced endometrial proliferation or hyperplasia
Corrected QT Interval (QTc on 12-Lead Electrocardiogram) No established target; stability from individual baseline Safety check: detects estrogen-mediated potassium channel blockade and acquired long QT syndrome before torsades de pointes can occur

Cadence: Baseline for all markers; resting 12-lead electrocardiogram at 2–4 weeks; fasting triglycerides, hs-CRP, ALT, AST, and complete blood count at 4 and 12–24 weeks; LDL and HDL cholesterol at 8 and 24 weeks; bone-specific alkaline phosphatase, vaginal cytology, and pelvic and breast ultrasound at 12–24 weeks (every 6 months).

Qualitative Assessment

  • Vasomotor diary: Daily hot flushes, night sweats, and sleep quality via the Modified Greene Climacteric Scale (MGCS) at baseline, 4, and 12 weeks.
  • Urogenital and bleeding log: Vaginal comfort and any vaginal spotting, mastodynia (breast pain), dizziness, or palpitations.